A small molecule Focal Adhesion Kinase (FAK) inhibitor, targeting Y397 site: 1-(2-Hydroxyethyl) -3, 5, 7-triaza-1-azoniatricyclo [18.104.22.168,7]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.
Carcinogenesis 2012 Mar 7; In press
Golubovskaya VM, Figel S, Ho BT, Johnson CP, Yemma M, Huang G, Zheng M, Nyberg C, Magis A, Ostrov DA, Gelman IH, Cance WG
Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY.
Focal Adhesion Kinase (FAK) is a protein tyrosine kinase that is overexpressed in most solid types of tumors and plays an important role in the survival signaling. Recently, we have developed a novel computer modeling combined with a functional assay approach to target the main autophosphorylation site of FAK (Y397). Using these approaches we identified 1-(2-Hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [22.214.171.124(3,7)]decane;bromide, called Y11 as a small molecule inhibitor targeting Y397 site of FAK. Y11 significantly and specifically decreased FAK autophosphorylation, directly bound to the N-terminal domain of FAK. In addition, Y11 decreased Y397-FAK autophosphorylation, inhibited viability and clonogenicity of colon SW620 and breast BT474 cancer cells, and increased detachment and apoptosis in vitro. Moreover, Y11 significantly decreased tumor growth in the colon cancer cell mouse xenograft model. Finally, tumors from the Y11-treated mice demonstrated decreased Y397-FAK autophosphorylation and activation of PARP and caspase-3. Thus, targeting the major autophosphorylation site of FAK with Y11 inhibitor is critical for development of cancer therapeutics and carcinogenesis field.